Manila Times Business
Simcere Pharmaceutical Enters into a Research Collaboration Agreement with Stanford Medicine to Develop Innovative Therapies for Patients with Idiopathic Pulmonary Fibrosis
SHANGHAI, June 12, 2026 /PRNewswire/ -- On May 29, 2026, Pacific Time, Simcere Pharmaceutical Group Limited (2096.HK) entered into a research collaboration agreement with Stanford Medicine to jointly advance an exploratory study in the respiratory field, with the aim of developing innovative therapies for patients with idiopathic pulmonary fibrosis (IPF). According to the agreement, Simcere Pharmaceutical will fund the exploratory research of this first-in-class novel molecule. Upon successful c
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Ateneo warns public to exercise discernment amid fake statement
1h ago
DepEd completes nationwide orientations on Learning Systems Policy Reforms
1h ago
DYWIDAG Group - DSI Holding GmbH has successfully priced a subsequent bond issuance and initiates written procedure under its existing bonds
1h ago
DYWIDAG Group Acquisition of Interspan
1h ago